PubRank

PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine

Clinical Trial ID NCT01441765

PubWeight™ 20.62‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01441765

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
2 PD-1 as a potential target in cancer therapy. Cancer Med 2013 1.98
3 Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012 1.51
4 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
5 Immune modulation for cancer therapy. Br J Cancer 2014 1.15
6 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
7 Potential biofluid markers and treatment targets for renal cell carcinoma. Nat Rev Urol 2013 0.91
8 Targeted therapy for renal cell carcinoma: The next lap. J Carcinog 2014 0.89
9 Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2015 0.88
10 PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 2014 0.85
11 Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med 2014 0.85
12 Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol 2016 0.84
13 Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. Biomed Res Int 2015 0.83
14 Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol 2015 0.82
15 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
16 Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology 2015 0.77
17 Medical treatment of renal cancer: new horizons. Br J Cancer 2016 0.76
18 Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs 2014 0.76
19 A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. J Immunother Cancer 2015 0.76
Next 100